Tauopathies: new perspectives and challenges

Y Zhang, KM Wu, L Yang, Q Dong, JT Yu - Molecular neurodegeneration, 2022 - Springer
Background Tauopathies are a class of neurodegenerative disorders characterized by
neuronal and/or glial tau-positive inclusions. Main body Clinically, tauopathies can present …

Diagnostic accuracy of a plasma phosphorylated tau 217 immunoassay for Alzheimer disease pathology

NJ Ashton, WS Brum, G Di Molfetta, AL Benedet… - JAMA …, 2024 - jamanetwork.com
Importance Phosphorylated tau (p-tau) is a specific blood biomarker for Alzheimer disease
(AD) pathology, with p-tau217 considered to have the most utility. However, availability of p …

Plasma biomarkers of Alzheimer's disease: a review of available assays, recent developments, and implications for clinical practice

MV Pais, OV Forlenza, BS Diniz - Journal of Alzheimer's …, 2023 - content.iospress.com
Recently, low-sensitive plasma assays have been replaced by new ultra-sensitive assays
such as single molecule enzyme-linked immunosorbent assay (Simoa), the Mesoscale …

Plasma biomarker strategy for selecting patients with Alzheimer disease for antiamyloid immunotherapies

N Mattsson-Carlgren, LE Collij, E Stomrud… - JAMA …, 2024 - jamanetwork.com
Importance Antiamyloid immunotherapies against Alzheimer disease (AD) are emerging.
Scalable, cost-effective tools will be needed to identify amyloid β (Aβ)–positive patients …

Biomarker-based prediction of longitudinal tau positron emission tomography in Alzheimer disease

A Leuzy, R Smith, NC Cullen, O Strandberg… - JAMA …, 2022 - jamanetwork.com
Importance There is currently no consensus as to which biomarkers best predict longitudinal
tau accumulation at different clinical stages of Alzheimer disease (AD). Objective To …

Equivalence of plasma p‐tau217 with cerebrospinal fluid in the diagnosis of Alzheimer's disease

J Therriault, S Servaes, C Tissot… - Alzheimer's & …, 2023 - Wiley Online Library
INTRODUCTION Plasma biomarkers are promising tools for Alzheimer's disease (AD)
diagnosis, but comparisons with more established biomarkers are needed. METHODS We …

Global neuropathologic severity of Alzheimer's disease and locus coeruleus vulnerability influences plasma phosphorylated tau levels

ME Murray, CM Moloney, N Kouri, JA Syrjanen… - Molecular …, 2022 - Springer
Background Advances in ultrasensitive detection of phosphorylated tau (p-tau) in plasma
has enabled the use of blood tests to measure Alzheimer's disease (AD) biomarker …

Evaluation of plasma biomarkers for a/T/N classification of Alzheimer disease among adults of Caribbean Hispanic ethnicity

LS Honig, MS Kang, AJ Lee… - JAMA Network …, 2023 - jamanetwork.com
Importance Cerebrospinal fluid (CSF) and plasma biomarkers can detect biological
evidence of Alzheimer disease (AD), but their use in low-resource environments and among …

Detection of brain tau pathology in Down syndrome using plasma biomarkers

S Janelidze, BT Christian, J Price, C Laymon… - JAMA …, 2022 - jamanetwork.com
Importance Novel plasma biomarkers, especially phosphorylated tau (p-tau), can detect
brain tau aggregates in Alzheimer disease. Objective To determine which plasma biomarker …

Long COVID as a tauopathy: of “Brain Fog” and “Fusogen Storms”

A Sfera, L Rahman… - International Journal of …, 2023 - mdpi.com
Long COVID, also called post-acute sequelae of SARS-CoV-2, is characterized by a
multitude of lingering symptoms, including impaired cognition, that can last for many months …